JoomFish-Language Selection
|
Options traders are gambling heavily that a looming advisory review of Cell Therapeutics' cancer drug pixantrone is going to lead to some very bad news for the struggling developer. Bloomberg reports that the traders are making ‘unprecedented' bets that the company's shares are poised to drop. "A lot of people think it's going to zero," Chris Rich, head options strategist at JonesTrading Institutional Services LLC, tells Bloomberg. "You have a study that's totally in question. That's the fear." The FDA is supposed to make its decision by April 23. Report |
Adebiotech
ALMA
Alosta
Alsace Biovalley
Amanda Conrad Translations
Actulabo
Hungarian Biotechnology Association
Px therapeutics
Vivactis Advance
Commission Européenne
Agence Nationale de la recherche
HAS
Inserm
Ministère de l'enseignement supérieur et de la recherche
Angels santé
Cerenis therapeutics
CISS
Fovea pharmaceuticals
IMS Health
Janssen Cilag
Paris Biotech Santé
Pharmaceutiques
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Europharm
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Oxo pharma
Px therapeutics
Px therapeutics
Px therapeutics
RWS GROUP
Px therapeutics
Sigma
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Px therapeutics
Advanstar
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
PMGROUP
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
STP Pharma
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
Adebiotech
